Compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
US-9464050-B2 · Oct 11, 2016 · US
Compositions for preventing and/or treating lysosomal storage disorders
US10035766B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10035766-B2 |
| Application number | US-201314083634-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 19, 2013 |
| Priority date | Oct 19, 2009 |
| Publication date | Jul 31, 2018 |
| Grant date | Jul 31, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.
First claim
Opening claim text (preview).
What is claimed: 1. A method for treating type 1 Gaucher's disease in a patient in need of such treatment, which comprises administering to the patient an effective amount of a compound of Formula III: wherein: R 1 is C(R 2 )(R 3 )(R 4 ); R 2 is hydrogen or fluorine; R 3 is fluorine; R 4 is fluorine, C 1-4 alkyl, or phenyl; R 7 is —OH; and R 8 is hydrogen. 2. The method of claim 1 , further comprising administering an effective amount of at least one other therapeutic agent. 3. The method of claim 2 , wherein the at least one other therapeutic agent is imiglucerase or 1,5-(butylimino)-1,5-dideoxy-D-glucitol. 4. The method of claim 1 , wherein R 2 is hydrogen. 5. The method of claim 1 , wherein R 2 is fluorine. 6. The method of claim 1 , wherein R 4 is fluorine. 7. The method of claim 1 , wherein R 4 is C 1-4 alkyl. 8. The method of claim 1 , wherein R 4 is phenyl.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Antioedematous agents; Diuretics · CPC title
Antianaemics · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10035766B2 cover?
- The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.
- Who is the assignee on this patent?
- Amicus Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D211/46. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).